InSite Vision Inc.

InSite Vision Announces Completion of the New Drug Application Submission to the U.S. FDA for BromSite http://phx.corporate-ir.net/phoenix.zhtml

InSite Vision Announces a new license agreement with Nicox for AzaSite, AzaSite Xtra and BromSite in Europe, Middle East and Africa. http://phx.corporate-ir.net/phoenix.zhtml

InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite http://phx.corporate-ir.net/phoenix.zhtml

InSite Vision Plans to Submit New Drug Application to FDA for DexaSite for the Treatment of Blepharitis in Adults. DexaSite NDA Submission Planned for 2015; AzaSite Plus Data and Endpoint Discussions with FDA Continue. http://phx.corporate-ir.net/phoenix.zhtml

InSite Announces Court Judgment Upholding All AzaSite Patents in Patent Infringement Lawsuit Against Sandoz Inc. http://bit.ly/18JQqFo

InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery: http://bit.ly/18oDCnV

Today we announced that the USPTO has issued a patent on DuraSite 2 which will provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2. Learn more: http://bit.ly/16SvQlY

InSite Vision Reports Second Quarter 2013 Financial Results http://bit.ly/17a6deq

InSite Vision to Report Second Quarter 2013 Financial Results on August 8, 2013 http://bit.ly/16dnRNL

Our CEO, Tim Ruane, will be presenting at the 8th Annual JMP Securities Healthcare Conference on July 9th at 12pm ET. Learn more: http://bit.ly/15dnbtG

Today we announced that we have received a Notice of Allowance from the United States Patent and Trademark Office for patent on DuraSite 2 ophthalmic drug delivery system. The patent is expected to provide protection to 2029 for DuraSite 2 and drugs formulated with DuraSite 2. Learn more and read the comments from our CEO, Tim Ruane, in today’s press release. http://bit.ly/15dklVA

We announced that we have regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra. Learn more about our latest news and read the comments from our CEO, Tim Ruane. http://bit.ly/14NZJmA

We are joining Merck (NYSE:MRK) and Pfizer (NYSE:PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals who recently filed an ANDA to market a generic version of AzaSite. Merck will take the lead and InSite Vision (OTCBB:INSV) will assume a monitoring role. The trial date for a similar lawsuit against Sandoz Inc. has been set for July 11th, 2013. http://bit.ly/13UbxB8